SNX25 is a member of the sorting nexin (SNX) superfamily, which plays crucial roles in membrane trafficking, cell signaling, and organelle dynamics. Our research has focused extensively on SNX25, demonstrating that SNX25-positive macrophages participate in inflammatory responses and pain perception through various signaling pathways. Atherosclerosis is now widely recognized as a chronic inflammatory disease of the vasculature, with macrophages serving as central contributors to its progression. These macrophages accumulate after internalizing oxidized low-density lipoproteins (oxLDL), transforming into foam cells that elicit inflammatory responses and promote atherosclerotic progression. To explore the impact of SNX25 on atherosclerosis, we induced the condition in apolipoprotein E-deficient (APOE(-/-)) mice using a high-fat diet. As expected, SNX25 expression was observed in macrophages within atherosclerotic plaques. In SNX25(+/-) mice on an APOE(-/-) genetic background, plaque size was significantly smaller than in their SNX25(+/+) counterparts. Furthermore, bone marrow transplantation from SNX25(+/-) mice into APOE(-/-) recipients resulted in a marked reduction in foam cell formation and accumulation compared to transplants from SNX25(+/+) donors. These histopathological findings suggest that SNX25 may regulate macrophage activity under pathological conditions, identifying a novel role for SNX25 in the pathogenesis of atherosclerosis.
Macrophage Deficiency of Sorting Nexin 25 Suppress Plaque Formation in Atherosclerotic Lesions in Mice.
巨噬细胞缺乏分选连接蛋白25可抑制小鼠动脉粥样硬化病变中的斑块形成
阅读:10
作者:Isonishi Ayami, Tatsumi Kouko, Okuda Hiroaki, Tanaka Tatsuhide, Hattori Tsuyoshi, Wanaka Akio
| 期刊: | Acta Histochemica et Cytochemica | 影响因子: | 1.800 |
| 时间: | 2025 | 起止号: | 2025 Apr 26; 58(2):101-106 |
| doi: | 10.1267/ahc.24-00055 | 研究方向: | 细胞生物学 |
| 疾病类型: | 动脉粥样硬化 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
